We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
-0.7%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$187M
AUM Growth
+$19.8M
Cap. Flow
+$29.5M
Cap. Flow %
15.78%
Top 10 Hldgs %
75.87%
Holding
40
New
13
Increased
12
Reduced
4
Closed
10

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$21.3M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$11.6M
3
BSTC
BioSpecifics Technologies Corp.
BSTC
+$8.57M
4
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$5.5M
5
CFMS
Conformis, Inc. Common Stock
CFMS
+$4.66M

Top Sells

Rank Stock Value
1
ENTA icon
Enanta Pharmaceuticals
ENTA
+$12.8M
2
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$9.71M
3
CDNA icon
CareDx
CDNA
+$6.75M
4
VCYT icon
Veracyte
VCYT
+$2.85M
5
SBBP
Strongbridge Biopharma plc.
SBBP
+$2.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.51%
2 Miscellaneous 1.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSTC
1
DELISTED
BioSpecifics Technologies Corp.
BSTC
$26.2M 14.02%
590,025
+204,071
+53% +$8.57M
CTIC
2
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$20.1M 10.75%
5,141,746
+3,306,908
+180% +$11.6M
AMRN
3
Amarin Corp
AMRN
$290M
$17.3M 9.29%
288,079
+287,202
+32,748% +$21.3M
VNDA icon
4
Vanda Pharmaceuticals
VNDA
$323M
$16.6M 8.89%
984,584
+99,584
+11% +$1.67M
APEN
5
DELISTED
Apollo Endosurgery, Inc.
APEN
$16.2M 8.65%
2,577,996
+17,682
+0.7% +$111K
VIVE
6
DELISTED
VIVEVE MED INC
VIVE
$14.1M 7.55%
3,850
– –
CPIX icon
7
Cumberland Pharmaceuticals
CPIX
$101M
$8.84M 4.74%
1,323,041
+16,130
+1% +$111K
BDSI
8
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$8.34M 4.47%
3,706,084
+60,593
+2% +$142K
CORV
9
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$7.52M 4.03%
3,241,550
+45,858
+1% +$72.5K
NVLN
10
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$6.51M 3.49%
1,860,000
+165,283
+10% +$701K
ALIM
11
DELISTED
Alimera Sciences
ALIM
$6.37M 3.41%
412,002
+174,675
+74% +$3.1M
DOVA
12
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$4.99M 2.67%
+184,000
New +$5.5M
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.37M 2.34%
1,593,119
-756,881
-32% -$2.19M
VCYT icon
14
Veracyte
VCYT
$3.59B
$4.3M 2.31%
773,889
-461,258
-37% -$2.85M
CFMS
15
DELISTED
Conformis, Inc. Common Stock
CFMS
$4.03M 2.16%
+111,108
New +$4.66M
OXFD
16
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$3.29M 1.76%
+263,974
New +$3.21M
VYNT
17
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
$2.92M 1.57%
11,818
-89
-0.7% -$25.1K
STDY
18
DELISTED
SteadyMed Ltd
STDY
$2.34M 1.26%
721,308
+103,583
+17% +$342K
IVTY
19
DELISTED
Invuity, Inc
IVTY
$1.95M 1.05%
+507,028
New +$2.32M
MTVA
20
MetaVia Inc
MTVA
$12.1M
$1.58M 0.85%
+4
New +$2.03M
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.18M 0.63%
+14,275
New +$1.62M
NVTA
22
DELISTED
Invitae Corporation
NVTA
$1.03M 0.55%
+219,022
New +$1.56M
ZSAN
23
DELISTED
Zosano Pharma Corporation
ZSAN
$1.01M 0.54%
+5,714
New +$1.91M
FOMX
24
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$666K 0.36%
+129,756
New +$781K
EOLS icon
25
Evolus
EOLS
$598M
$535K 0.29%
+59,229
New +$678K
1
2

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Stonepine Capital Management held 40 positions worth $187M, up 12% from $167M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Stonepine Capital Management deployed $29.5M of net new capital in Q1 2018, opening 13 new positions and adding to 12 existing holdings. Its largest new stake was Dova Pharmaceuticals, Inc. Common Stock: 184,000 shares worth $4.99M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Veracyte, an estimated $2.85M trimmed.

  • Stonepine Capital Management's largest Q1 2018 buy was Dova Pharmaceuticals, Inc. Common Stock: 184,000 shares worth $4.99M.
  • Stonepine Capital Management added most to Amarin Corp in Q1 2018, an estimated $21.3M increase.
  • Stonepine Capital Management's biggest Q1 2018 reduction was Veracyte, cutting an estimated $2.85M.
  • Stonepine Capital Management fully exited Enanta Pharmaceuticals in Q1 2018, selling an estimated $12.8M.
  • Stonepine Capital Management's ten largest holdings make up 76% of its $187M portfolio in Q1 2018.
  • Stonepine Capital Management opened 13 new positions and closed 10 in Q1 2018.
  • Stonepine Capital Management's portfolio value rose 12% quarter-over-quarter to $187M.

Based on Stonepine Capital Management's 13F filing for Q1 2018, filed 14 May 2018.